Targeting Exonuclease Resistant RNA to Develop Zika Virus Therapeutics
Award amount
$299,236Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Nymirum, Inc.
- Proposal award date
- 2018-01-01
- Contract end date
- 2019-10-31
- UEI
- ZJRRLDJNHJC9
- Solicitation number
- PA16-302
- Topic code
- NIAID
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Developing Drug-like Small Molecules that Target Toxic Repeat RNAs to Alleviate Myotonic Dystrophy Type 1-derived Mis-Splicing
- A Small Molecule Drug Discovery Platform to Target Cancer Causing microRNAs
- An Automated RNA 3D Structure Determination System
- An Automated RNA 3D Structure Determination System
- Modular Ultrasonic Beacon System (MUBS) for Ultrasound-guided Interventional Surg
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
6 SBIR/STTR records share this UEI (2013–2020). Reported award amounts total $2,813,579. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services